一项针对淋巴结阳性乳腺癌术后放疗联合或不联合内乳淋巴结照射的III期多中心随机试验(POTENTIAL)中的质量保证:计划基准病例
POTENTIAL试验是一项评估高危乳腺癌患者内乳淋巴结(IMN)照射价值的多中心随机III期试验。所有参与机构对同一基准病例按方案制定放疗计划,经质量保证团队评估后重新提交修订计划。26家机构的分析显示,修订后胸壁、锁骨上区加腋窝及IMN区靶区剂量覆盖的方案符合率均显著提高,部分危及器官符合率也显著改善。
要点
- 26家机构参与基准病例计划,修订后胸壁、锁骨上区加腋窝及IMN区靶区剂量覆盖符合率显著提高。
- 心脏Dmean、左前降支V40Gy、同侧肺V5Gy和胃V5Gy的符合率在最终提交中显著改善。
- 计划基准病例有助于保障多中心试验的放疗计划质量。
核心结论
- 修订后主要偏差被纠正,方案符合率显著提高,凸显了计划基准病例对保障多中心试验计划质量的重要性。
研究设计与样本
- 多中心、随机、III期试验POTENTIAL的质量保证项目,所有参与机构对同一基准病例按方案制定放疗计划。
- 计划经质量保证团队评估后,各机构重新提交修订计划;共分析26家机构的计划。
主要发现
- 首次提交中发现一些主要偏差。
- 最终提交时胸壁、锁骨上区加腋窝和IMN区(PTVim)靶区剂量覆盖的方案符合率分别为96.2% vs. 69.2%、100% vs. 76.9%和88.4% vs. 53.8%,均显著提高。
- 危及器官方面,心脏Dmean、左前降支V40Gy、同侧肺V5Gy和胃V5Gy的符合率显著改善。
- 首次与最终提交中,PTVim V100%均值分别为79.9% vs. 92.7%。
- 心脏Dmean均值在大分割放疗中分别为11.5 Gy vs. 9.7 Gy,在常规分割放疗中分别为11.5 Gy vs. 11.0 Gy。
关键数值与推荐
- 胸壁靶区剂量覆盖符合率:最终提交96.2% vs. 首次提交69.2%。
- 锁骨上区加腋窝靶区剂量覆盖符合率:最终提交100% vs. 首次提交76.9%。
- IMN区(PTVim)靶区剂量覆盖符合率:最终提交88.4% vs. 首次提交53.8%。
- PTVim V100%均值:最终提交92.7% vs. 首次提交79.9%。
- 心脏Dmean均值:大分割放疗最终提交9.7 Gy vs. 首次提交11.5 Gy;常规分割放疗最终提交11.0 Gy vs. 首次提交11.5 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the planning benchmark case results of the POTENTIAL trial-a multicenter, randomized, phase 3 trial-to evaluate the value of internal mammary nodal (IMN) irradiation for patients with high-risk breast cancer. METHODS: All participating institutions were provided the outlines of one benchmark case, and they generated radiation therapy plans per protocol. The plans were evaluated by a quality assurance team, after which the institutions resubmitted their revised plans. The information on beams arrangement, skin flash, inhomogeneity corrections, and protocol compliance was assessed in the first and final submission. RESULTS: The plans from 26 institutions were analyzed. Some major deviations were found in the first submission. The protocol compliance rates of dose coverage for the planning target volume of chest wall, supraclavicular fossa plus axilla, and IMN region (PTVim) were all significantly improved in the final submission, which were 96.2% vs. 69.2%, 100% vs. 76.9%, and 88.4% vs. 53.8%, respectively. For OARs, the compliance rates of heart Dmean, left anterior descending coronary artery V40Gy, ipsilateral lung V5Gy, and stomach V5Gy were significantly improved. In the first and final submission, the mean values of PTVim V100% were 79.9% vs. 92.7%; the mean values of heart Dmean were 11.5 Gy vs. 9.7 Gy for hypofractionated radiation therapy and 11.5 Gy vs. 11.0 Gy for conventional fractionated radiation therapy, respectively. CONCLUSION: The major deviations were corrected and protocol compliance was significantly improved after revision, which highlighted the importance of planning benchmark case to guarantee the planning quality for multicenter trials.
引用
- Song YC, Hu ZH, Yan XN, et al. Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case. Radiat Oncol. 2023. PMID: 38031125. doi:10.1186/s13014-023-02379-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。